A practical reference on AOD-9604: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-07-08 and is reviewed periodically as new material appears.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Most RTGs use 238Pu, which decays with a half-life of 87.7 years. RTGs using this material therefore diminish in power output by a factor of 1 – (1/2)1/87.7, or 0.787%, per year. One example is the MHW-RTG used by the Voyager probes. In the year 2000, 23 years after production, the radioactive material inside the RTG had decreased in power by 16.6%, i.e. providing 83.4% of its initial output; starting with a capacity of 470 W, after this length of time it would have a capacity of only 392 W. A related loss of power in the Voyager RTGs is the degrading properties of the bi-metallic thermocouples used to convert thermal energy into electrical energy; the RTGs were working at about 67% of their total original capacity instead of the expected 83.4%. By the beginning of 2001, the power generated by the Voyager RTGs had dropped to 315 W for Voyager 1 and to 319 W for Voyager 2. By 2022, these numbers had dropped to around 220 W. NASA has developed a multi-mission radioisotope thermoelectric generator (MMRTG) in which the thermocouples would be made of skutterudite, a cobalt arsenide (CoAs3), which can function with a smaller temperature difference than the current tellurium-based designs. This would mean that an otherwise similar RTG would generate 25% more power at the beginning of a mission and at least 50% more after seventeen years. NASA hopes to use the design on the next New Frontiers mission.
The five other countries, including the second and third largest beef producers, France and the United Kingdom, respectively, permitted their use. This had resulted in disputes, with countries that had no prohibitions arguing that the restrictions by the others acted as non-tariff trade barriers. In response to the public outcry, in combination with the discovery that DES was a teratogen, in 1980 the EU began to issue regulations, beginning with prohibiting the use of stilbenes and thyrostatics by the European Community Council of Agriculture Ministers in 1980, and commissioning of a scientific study into the use of estradiol, testosterone, progesterone, trenbolone, and zeranol in 1981. The European Consumers' Organisation (BEUC) lobbied for a total ban upon growth hormones, opposed, with partial success, by the pharmaceutical industry. (In 1987 the European Federation of Animal Health (FEDESA), formed to represent, amongst other things, companies that manufactured growth hormones.) Neither European farmers nor the meat processing industry took a stance on the matter. With the help of the BEUC consumer boycotts of veal products, sparked by the Italian scandals and similar reports in France and Germany, spread across the EU, causing companies such as Hipp and Alete to withdraw their veal products, while veal prices dropped in France, Belgium, West Germany, Ireland, and the Netherlands. Because of the fixed purchases guaranteed by the EU's Common Agricultural Policy, ECU 10 million came out of the EU budget.
In Kwannon's first appearance, using the codename Revanche, she traveled to the United States to confront Braddock, believing herself to be the real Betsy Braddock due to amnesia caused by the body swap. She discovered that she was formerly the Hand's prime assassin before incurring brain damage and falling comatose as a result of a battle with her lover Matsu'o Tsurayaba, a high-ranking member of the Hand. In hopes that, due to Kwannon's low-level psychic abilities, the powers of the high-level telepath Betsy Braddock would be able to save her life, Tsurayaba sought the help of the sorceress Spiral, who instead transferred the women's minds into each other's bodies rather than simply recovering Kwannon. After accepting that she is not the original Betsy Braddock, Kwannon becomes a member of the X-Men, shortly thereafter contracting the Legacy Virus. As the disease progressed, Kwannon's psychic abilities increased, allowing her to clarify her own distorted memory. Choosing to die on her own terms, Kwannon confronts Tsurayaba, who complies with her request to kill her rather than waiting to succumb to the disease. Following the Hunt for Wolverine, when Braddock was restored to her original body, Kwannon was reborn in her original body as well. Claiming the codename Psylocke for herself, Kwannon became a citizen of the mutant nation of Krakoa. After the apparent murder of her long-lost daughter by a threatening artificial intelligence called Apoth, Psylocke assembled a new team of Fallen Angels with X-23 and Cable.
The body of the bowfin is elongated and cylindrical, with the sides and back olive to brown in color, often with vertical bars and dark reticulations or another camouflaged pattern. The dorsal fin has horizontal bars, and the caudal fin has irregular, vertical bars. The underside is white or cream, and the paired fins and anal fin are bright green. During larval stage, hatchlings from about 7–10 mm (0.28–0.39 in) total length are black and tadpole-like in appearance. Around 25 mm (0.98 in) total length, they have been described as looking like miniature placoderms. They grow quickly, and typically leave the nest within 4 to 6 weeks after hatching. Young males have a black eyespot on the base of the tail (caudal peduncle) that is commonly encircled by an orange-yellowish border, while the female's is black, if present at all. The purpose of the eyespot thought to be to confuse predators, deflecting attacks away from the head of the fish to its tail, which affords the bowfin an opportunity to escape predation. The bowfin is so named for its long, undulating dorsal fin consisting of 145 to 250 rays that runs from the middle of the back to the base of the tail. The skull of the bowfin is made of two layers, the dermatocranium and the chondrocranium. The chondrocranium layer cannot be seen because it is located below the dermal bones. The bowfin skull is made up of 28 fused bones, which compose the dermatocranium. The roof of the mouth is made up of three bones, the ectopterygoid, the palantine, and the vomer.
Bonaparte's reign over Europe sowed the seeds for the founding of the nation-states of Germany and Italy by starting the process of consolidating city-states, kingdoms and principalities. At the end of the war, Denmark was forced to cede Norway to Sweden mainly as a compensation for the loss of Finland which the other coalition members agreed to, but because Norway had signed its own constitution on 17 May 1814 Sweden initiated the Swedish–Norwegian War (1814). The war was a short one taking place between 26 July – 14 August 1814 and was a Swedish victory that put Norway into a personal union with Sweden. The union was peacefully dissolved in 1905. The United Kingdom of the Netherlands created as a buffer state against France dissolved rapidly with the independence of Belgium in 1830.
Sources: en.wikipedia.org
Alzheimer's disease (AD) can be definitively diagnosed only with histopathological findings; in the absence of autopsy or brain biopsy, clinical diagnoses of AD are "possible" or "probable", based on other findings. Up to 23% of those clinically diagnosed with AD may be misdiagnosed and may have pathology suggestive of another condition with symptoms that mimic those of AD.
=== Immunosuppression === Immunosuppression is used inconsistently in Sydenham's chorea. The model of an autoimmune disorder would support its use. One randomized controlled trial of steroids from Paz, Brazil in 2006 (22 cases) showed remission reduced to 54 days from 119 days. Various other reports of use of oral or IV steroids from Israel, Italy and Brazil. Immunoglobulin has been used in Holland and South Africa. Some improvement can be seen within a few days of IV steroids. In Italy, prednisolone reduced average duration of symptoms from 9 weeks to 4 weeks, and these were severe cases. South African group found less neuropsychiatric complications at 6 months with IVIG treatment (IVIG preferred due to fear of TB reactivation).
== Gymnastics scandals == Age controversies in gymnastics USA Gymnastics sex abuse scandal – former USA Gymnastics national team doctor, Larry Nassar, was accused of sexual abuse by more than 150 girls and women. Nassar was sentenced to 60 years in prison on federal child pornography charges in December 2017, and was sentenced to 80 to 300 years in prison after two separate trials on sexual assault charges in January 2018, to be served consecutively.
Despite early success, some of the main hinderances of the UPP project were police abuses and disappearances that occurred. One of the most prominent cases of this was the disappearance of Amarildo Souza, a bricklayer from the Rocinha favela. Souza, 42, had been fishing the morning of his disappearance and decided to go into the favela to get produce when he was confronted by UPP officers. Souza was taken for questioning and subsequently never returned home. Souza was well known throughout Rocinha, leading to public outcry at his disappearance and a lack of response by the UPP unit. After more than two months of public outcry, an investigation was opened into his disappearance, where twenty-four UPP officers and the UPP commander were found accused of torture, concealing a body, procedural fraud, and conspiracy. In the subsequent trial, twelve officers would be found guilty of torture, procedural fraud, and concealing a body. Despite the investigation and criminal case, the UPP suffered weakened support from favela residents, who felt both anger and fear at the actions of the local UPP unit. Coupled with insufficient training and poorly strategized growth of the units, the UPP continued to fail as insignificant funding heavily derailed the project, which could not perform what it was intended to. With the weakening of the UPP, criminal organizations could again attempt to reclaim their territories through shootouts and confrontations, but were this time more successful.
Co2(CO)8 unlike the majority of the other 18 VE transition metal carbonyls is sensitive to oxygen. Group 10 elements with 10 valence electrons form tetracarbonyls such as Ni(CO)4. Curiously Pd(CO)4 and Pt(CO)4 are not stable.
Sources: en.wikipedia.org
According to Alexander Shulgin, conversion of the allylbenzenes into amphetamines could account for nutmeg's psychoactive effects, whereas the terpene fraction could be responsible for the drug's toxic effects, though this theory remains unconfirmed and has since been contradicted by various findings. The constituents of nutmeg were comprehensively reviewed in 2016.
== History == Students Michael Schrader, Livio Valenti, Kathryn Kosuda, and Patrick Ho started Vaxess in December 2011, based on a technology created by David Kaplan and Fiorenzo Omenetto. Schrader graduated with an MBA from Harvard Business School in 2012. Valenti attended the John F. Kennedy School of Government. Kosuda had been a Harvard postdoctoral fellow in chemistry, and Patrick Ho had earned a J.D in 2012. In 2012, Vaxess was awarded $25,000 from Harvard Business School for Harvard's Business Plan Contest in the Business Ventures Track. Vaxess Technologies was a semi-finalist for MIT's $100K Entrepreneurship Competition in the Life Sciences section. In 2012, it won the Harvard President's Challenge in the Global Health section and was awarded $70,000. The company was selected as a finalist for two 2013 MassTLC Awards, Start-Up to Watch and Innovative Technology of the Year: Healthcare/Life Sciences. In May 2013, Vaxess received $3.75M in funding from Norwich Ventures and an undisclosed amount of money from angel investor Jeffrey Walker. In August 2013, the company announced that it would be moving out of Harvard's Innovation Lab to a new location at LabCentral in Cambridge. In December 2013, the Massachusetts Life Sciences Center awarded $1.5M to local startups. Vaxess received $1M of that amount which is the most that the MLSC's Accelerator Loan Program will lend to one organization.
Liquid chromatography–mass spectrometry (LC–MS) is an analytical chemistry technique that combines the physical separation capabilities of liquid chromatography (or HPLC) with the mass analysis capabilities of mass spectrometry (MS). Coupled chromatography–MS systems are popular in chemical analysis because the individual capabilities of each technique are enhanced synergistically. While liquid chromatography separates mixtures with multiple components, mass spectrometry provides spectral information that may help to identify (or confirm the suspected identity of) each separated component. MS is not only sensitive, but provides selective detection, relieving the need for complete chromatographic separation. LC–MS is also appropriate for metabolomics because of its good coverage of a wide range of chemicals. This tandem technique can be used to analyze biochemical, organic, and inorganic compounds commonly found in complex samples of environmental and biological origin. Therefore, LC–MS may be applied in a wide range of sectors including biotechnology, environment monitoring, food processing, and pharmaceutical, agrochemical, and cosmetic industries. Since the early 2000s, LC–MS (or more specifically LC–MS/MS) has also begun to be used in clinical applications. In addition to the liquid chromatography and mass spectrometry devices, an LC–MS system contains an interface that efficiently transfers the separated components from the LC column into the MS ion source. The interface is necessary because the LC and MS devices are fundamentally incompatible.
=== Early radiation consequences === The discovery of X-rays by Wilhelm Conrad Röntgen (1845-1923) in 1895 led to extensive experimentation by scientists, physicians, and inventors. The first X-ray machines produced extremely unfavorable radiation spectra for imaging with extremely high skin doses. In February 1896, John Daniel and William Lofland Dudley (1859–1914) of Vanderbilt University conducted an experiment in which Dudley's head was X-rayed, resulting in hair loss. Herbert D. Hawks, a graduate of Columbia University, suffered severe burns on his hands and chest during demonstration experiments with X-rays. Burns and hair loss were reported in scientific journals. Nikola Tesla (1856–1943) was one of the first researchers to explicitly warn of the potential dangers of X-rays in the Electrical Review on May 5, 1897 - after initially claiming them to be completely harmless. He suffered massive radiation damage after his experiments. Nevertheless, some doctors at the time still claimed that X-rays had no effect on humans. Until the 1940s, X-ray machines were operated without any protective safeguards. Röntgen himself was spared the fate of the other X-ray users by habit. He always carried the unexposed photographic plates in his pockets and found that they were exposed if he remained in the same room during the exposure. So he regularly left the room when he took X-rays.
New evidence shows that cffDNA test failure rate is higher, fetal fraction (proportion of fetal versus maternal DNA in the maternal blood sample) is lower and PPV for trisomies 18, 13 and SCA is decreased in IVF pregnancies compared to those conceived spontaneously.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.